|
|
News Breaks | | | | March 15, 2013 | | 07:20 EDT |  | ONTY | Oncothyreon price target lowered to $4 from $11 at Cantor
Cantor reduced its price target on Oncothyreon as the firm believes that the company's Stimuvax drug is no longer a commercial candidate. However, the firm believes that Oncothyreon's cancer treatment PX-866, along with its cash, could be worth about $3.90 per share. The firm maintains a Buy rating on the stock. | |
|
News For ONTY From The Last 14 Days Check below for free stories on ONTY the last two weeks. |
|
|
| There are no results for ONTY |
|
|
|
|
|
|
